Vidarbha News

DelveInsight Highlights Major Advances, Transformative Therapies, and 5+ Leading Players Wheeling the Meningioma Clinical Trial Pipeline Landscape

 Breaking News
  • No posts were found

DelveInsight Highlights Major Advances, Transformative Therapies, and 5+ Leading Players Wheeling the Meningioma Clinical Trial Pipeline Landscape

September 19
02:20 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 5+ Leading Players Wheeling the Meningioma Clinical Trial Pipeline Landscape

DelveInsight’s, “Meningioma Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Meningioma Pipeline Report

  • DelveInsight’s Meningioma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment.
  • The leading companies working in the Meningioma Market include NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
  • Promising Meningioma Pipeline Therapies in the various stages of development include Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI), NEO100, Cabozantinib, Pembrolizumab, and others.
  • March 2023: Neonc Technologies Inc. announced a study of Phase 2 Clinical Trials for NEO100. This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma.
  • May 2023: Baptist Health South Florida announced a study of Phase 2 Clinical Trials for Cabozantinib. A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma.

 

Request a sample and discover the recent advances in Meningioma Treatment Drugs @ Meningioma Infection Pipeline Report

 

The Meningioma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Meningioma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Meningioma clinical trial landscape.

 

Meningioma Overview

Meningioma is the most common intracranial tumor that originate from arachnoid cap cells present within the web -like membrane of the protective layer (meninges) covering the brain and spinal cord. Most meningiomas grow very slowly, often over many years without causing any symptoms.

 

Find out more about Meningioma Treatment Drugs @ Drugs for Meningioma Treatment

 

Meningioma Emerging Drugs Profile

  • Gleolan: NX Devolopment Corp
  • Nivolumab: Bristol-Myers Squibb

 

Meningioma Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Meningioma. The Meningioma companies which have their Meningioma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, NX Devolopment Corp and others.

 

Learn more about the emerging Meningioma Pipeline Therapies @ Meningioma Clinical Trials Assessment

 

Scope of the Meningioma Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
  • Meningioma Pipeline Therapies- Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI), NEO100, Cabozantinib, Pembrolizumab, and others.

 

Dive deep into rich insights for new drugs for Meningioma treatment, Visit @ Meningioma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Meningioma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Meningioma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Meningioma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Gleolan: Nx Development Corp.
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Nivolumab: Bristol-Myers Squibb
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Meningioma Key Companies
  19. Meningioma Key Products
  20. Meningioma- Unmet Needs
  21. Meningioma- Market Drivers and Barriers
  22. Meningioma- Future Perspectives and Conclusion
  23. Meningioma Analyst Views
  24. Meningioma Key Companies
  25. Appendix

 

For further information on the Meningioma pipeline therapeutics, reach out to Meningioma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Categories